News

Technology News

Alere Licenses VitaPath Genetics Assay

Thursday, August 11, 2011 5:02:00 AM PDT | VentureDeal Staff
   Foster City, California  --  Medical device and diagnostics company Alere has announced a licensing agreement with VitaPath Genetics.

Alere has licensed the spina bifida risk assessment assay worldwide marketing rights, which is expected to be commercially launched in 2012.

The assay is a test that identifies risk in women of childbearing age for the birth defect spina bifida, which may be prevented with high dose folic acid treatment.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1